Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Marjolein van Ballegooijen"'
Autor:
Elizabeth M. Webber, Katrina A.B. Goddard, Ned Calonge, Suman Kundu, W. David Dotson, Doris T. Zallen, Steffie K. Naber, Karen M. Kuntz, Ann G. Zauber, Nora B. Henrikson, Marjolein van Ballegooijen, Marc S. Williams, A. Cecile J.W. Janssens, Theodore G. Ganiats, Iris Lansdorp-Vogelaar
Publikováno v:
Naber, S K, Kundu, S, Kuntz, K M, Dotson, W D, Williams, M S, Zauber, A G, Calonge, N, Zallen, D T, Ganiats, T G, Webber, E M, Goddard, K A B, Henrikson, N B, Van Ballegooijen, M, Janssens, A C J W & Lansdorp-Vogelaar, I 2020, ' Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk : Current status and future potential ', JNCI Cancer Spectrum, vol. 4, no. 1, pkz086 . https://doi.org/10.1093/jncics/pkz086
JNCI Cancer Spectrum, 4(1):UNSP pkz086. Oxford University Press
JNCI Cancer Spectrum
JNCI Cancer Spectrum, 4(1):pkz086
JNCI Cancer Spectrum, 4(1):UNSP pkz086. Oxford University Press
JNCI Cancer Spectrum
JNCI Cancer Spectrum, 4(1):pkz086
Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current uniform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c9a8f846ad5bd81d4fa1f7f060e675
https://hdl.handle.net/10919/98477
https://hdl.handle.net/10919/98477
Autor:
Christian Ramakers, Marieke A.M. Frasa, Annemieke W.J. Opstal-van Winden, Gerrit A. Meijer, Ernst J. Kuipers, W.M.U. Van Grevenstein, Tj. Wiersma, Iris Lansdorp-Vogelaar, Harry J. de Koning, Geraldine R. Vink, Esther Toes-Zoutendijk, Evelien Dekker, J.A. Otte, Iris D. Nagtegaal, A. van der Beek, J. van Bergeijk, Marie-Louise F. van Velthuysen, L.H.J. Jacobs, E. J. R. de Graaf, Ad A.M. Masclee, Marloes A. G. Elferink, Folkert J. van Kemenade, Manon C.W. Spaander, Arthur I. Kooyker, Marjolein van Ballegooijen, Harriët van Veldhuizen, Monique E. van Leerdam, Jaap Stoker, Maarten Thomeer, Anneke J van Vuuren, Maaike Buskermolen
Publikováno v:
Clinical Gastroenterology and Hepatology, 18(7), 1493-1500. W.B. Saunders
Clinical gastroenterology and hepatology, 18(7), 1493-1500. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 18, 1493-1500
Clinical Gastroenterology and Hepatology, 18(7), 1493-1500. ELSEVIER SCIENCE INC
Clinical Gastroenterology and Hepatology, 18, 7, pp. 1493-1500
Clinical gastroenterology and hepatology, 18(7), 1493-1500. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 18, 1493-1500
Clinical Gastroenterology and Hepatology, 18(7), 1493-1500. ELSEVIER SCIENCE INC
Clinical Gastroenterology and Hepatology, 18, 7, pp. 1493-1500
Contains fulltext : 220797pub.pdf (Publisher’s version ) (Open Access) BACKGROUND & AIMS: We evaluated the incidence of interval cancers between the first and second rounds of colorectal cancer (CRC) screening with the FOB-Gold fecal immunochemical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b017313265cd95870ad87d6340feec58
https://pure.eur.nl/en/publications/04087563-cc46-40d9-8d37-54d5598cb1b9
https://pure.eur.nl/en/publications/04087563-cc46-40d9-8d37-54d5598cb1b9
Autor:
Linda J.W. Bosch, Iris Lansdorp-Vogelaar, Veerle Melotte, Manon van Engeland, S. Lucas Goede, Gerrit A. Meijer, Beatriz Carvalho, Harry J. de Koning, Marjolein van Ballegooijen
Publikováno v:
Clinical Gastroenterology and Hepatology, 16(4), 504-512.e11. W.B. Saunders Ltd
Lansdorp-Vogelaar, I, Goede, S L, Bosch, L J W, Melotte, V, Carvalho, B, van Engeland, M, Meijer, G A, de Koning, H J & van Ballegooijen, M 2018, ' Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening ', Clinical Gastroenterology and Hepatology, vol. 16, no. 4, pp. 504-512.e11 . https://doi.org/10.1016/j.cgh.2017.07.011
Clinical gastroenterology and hepatology, 16(4), 504-12. Elsevier Science
Clinical Gastroenterology and Hepatology, 16(4), 504-+. W.B. Saunders
Lansdorp-Vogelaar, I, Goede, S L, Bosch, L J W, Melotte, V, Carvalho, B, van Engeland, M, Meijer, G A, de Koning, H J & van Ballegooijen, M 2018, ' Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening ', Clinical Gastroenterology and Hepatology, vol. 16, no. 4, pp. 504-512.e11 . https://doi.org/10.1016/j.cgh.2017.07.011
Clinical gastroenterology and hepatology, 16(4), 504-12. Elsevier Science
Clinical Gastroenterology and Hepatology, 16(4), 504-+. W.B. Saunders
BACKGROUND & AIMS: Biomarker assays could increase the accuracy of noninvasive detection of colorectal cancer (CRC); fecal immunochemical tests (FITs) are estimated to miss 27%-47% of CRCs and 70%-80% of advanced adenomas per round of screening. We i
Autor:
Douglas A. Corley, Iris Lansdorp-Vogelaar, M.P.H. Chyke A. Doubeni M.D., Reinier G.S. Meester, Marjolein van Ballegooijen, Ann G. Zauber
Publikováno v:
International Journal of Cancer, 141(11), 2359-2367. Wiley-Liss Inc.
Colonoscopy quality, as measured by adenoma detection rates, varies widely across providers and is inversely related with patients' post-colonoscopy cancer risk. This has unknown consequences for the benefits of faecal immunochemical testing (FIT) ve
Autor:
Harry J. de Koning, Iris Lansdorp-Vogelaar, Ernst J. Kuipers, Else-Mariëtte B. van Heijningen, Katharina Biermann, Frank van Hees, Ewout W. Steyerberg, Marjolein van Ballegooijen
Publikováno v:
Endoscopy, 48(6), 563-570. Georg Thieme Verlag
Background and study aims: Current surveillance guidelines risk stratify patients with adenoma by using only one or two factors: adenoma multiplicity or presence of an advanced adenoma characteristic. Combinations of adenoma characteristics are not c
Autor:
Doris T. Zallen, Theodore G. Ganiats, Elizabeth M. Webber, Karen M. Kuntz, A. Cecile J.W. Janssens, Marjolein van Ballegooijen, Steffie K. Naber, Iris Lansdorp-Vogelaar, Nora B. Henrikson, Marc S. Williams, Ann G. Zauber, Ned Calonge, Katrina A.B. Goddard
Publikováno v:
Gastroenterology, vol 154, iss 1
Gastroenterology, 154(1), 105-116.e20. W.B. Saunders Ltd
Gastroenterology, 154(1), 105-+. W.B. Saunders
Gastroenterology, 154(1), 105-116.e20. W.B. Saunders Ltd
Gastroenterology, 154(1), 105-+. W.B. Saunders
Background & aimsRelative risk of colorectal cancer (CRC) decreases with age among individuals with a family history of CRC. However, no screening recommendations specify less frequent screening with increasing age. We aimed to determine whether such
Autor:
Lawrence Paszat, Jean H E Yong, Linda Rabeneck, Frank van Hees, Simon L. Goede, Marjolein van Ballegooijen, Jeffrey S Hoch, Ann G. Zauber, Jill Tinmouth, Iris Lansdorp-Vogelaar
Publikováno v:
International Journal of Cancer. 137:1119-1127
textabstractIn the province-wide colorectal cancer (CRC) screening program in Ontario, Canada, individuals with a family history of CRC are offered colonoscopy screening and those without are offered guaiac fecal occult blood testing (gFOBT, Hemoccul
Autor:
Joanne E. Schottinger, Miriam P. van der Meulen, Iris Lansdorp-Vogelaar, Christopher D. Jensen, Reinier G.S. Meester, Chyke A. Doubeni, Douglas A. Corley, Virginia P. Quinn, Ann G. Zauber, Theodore R. Levin, Marjolein van Ballegooijen
Publikováno v:
JAMA-Journal of the American Medical Association, 313(23), 2349-2358. American Medical Association
Importance Colonoscopy is the most commonly used colorectal cancer screening test in the United States. Its quality, as measured by adenoma detection rates (ADRs), varies widely among physicians, with unknown consequences for the cost and benefits of
Autor:
Virginie G. Daguisé, Iris Lansdorp-Vogelaar, Franklin G. Berger, Alex van der Steen, Marjolein van Ballegooijen, Gailya P Walter, Amy B. Knudsen, Frank van Hees, Ann G. Zauber, Karen M. Kuntz
Publikováno v:
Health Services Research, 50(3), 768-789. Wiley-Blackwell Publishing Ltd
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Each year almost 150,000 new CRC cases are diagnosed and more than 50,000 people die from the disease (Siegel, Naishadham, and Jemal 2013). Several randomized c
Autor:
Theodore G. Ganiats, Katrina A.B. Goddard, Evelyn P Whitlock, Iris Lansdorp-Vogelaar, Nora B. Henrikson, Ann G. Zauber, Doris T. Zallen, Marc S. Williams, Marjolein van Ballegooijen, Aaron Scrol, Ned Calonge, Margaret Piper, Elizabeth M. Webber, A. Cecile J.W. Janssens
Publikováno v:
Genetics in Medicine, 17(9), 702-712. Lippincott Williams & Wilkins
Genetics in medicine : official journal of the American College of Medical Genetics, vol 17, iss 9
Genetics in medicine : official journal of the American College of Medical Genetics, vol 17, iss 9
Purpose: Family history of colorectal cancer (CRC) is a known risk factor for CRC and encompasses both genetic and shared environmental risks. Methods: We conducted a systematic review to estimate the impact of family history on the natural history o